Ethinylestradiol/norethisterone (EE/NET), or ethinylestradiol/norethindrone, is a combination birth control pill which contains ethinylestradiol (EE), an estrogen and norethisterone (NET), a progestin. It is used for birth control, symptoms of menstruation, endometriosis, and menopausal symptoms. Other uses include acne. It is taken by mouth. Some preparations of EE/NET additionally contain an iron supplement in the form of ferrous fumarate.Side effects can include nausea, headache, blood clots, breast pain, depression, and liver problems. Use is not recommended during pregnancy, the initial three weeks after childbirth, and in those at high risk of blood clots. It, however, may be started immediately after a miscarriage or abortion. Smoking while using combined birth control pills is not recommended. It works by stopping ovulation, making the uterus not suitable for implantation, and making the mucus at the opening to the cervix thick.This combination pill was approved for medical use in the United States in 1964. It is on the World Health Organizations List of Essential Medicines. It is available as a generic medication. It is marketed under a large number of brand names. In 2020, it was the 45th most commonly prescribed medication in the United States, with more than 14 million prescriptions. See also
Mestranol/norethisterone
Oral contraceptive formulations
List of combined sex-hormonal preparations


== References ==
Such failure is called biochemical failure and is defined as a PSA reading of 2.0 ng/mL above nadir (the lowest reading taken post primary treatment).As of August 2014, a clinical trial administering sipuleucel-T in conjunction with ipilimumab (Yervoy) was tracking subjects but no longer enrolling new subjects; the trial evaluates the clinical safety and anti-cancer effects (quantified in PSA, radiographic and T cell response) of the combination therapy in patients with advanced prostate cancer. References
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute. Further reading
Huber ML, Haynes L, Parker C, Iversen P (February 2012). "Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer". Journal of the National Cancer Institute. 104 (4): 273–9. doi:10.1093/jnci/djr514. PMC 3283534. PMID 22232132. "Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon". Drugs in R&D. 7 (3): 197–201. 2006. doi:10.2165/00126839-200607030-00006. PMID 16752945. External links
"Sipuleucel-T". Drug Information Portal. U.S. National Library of Medicine.